Lixte Biotechnology Holdings (Lixte Biotechnology Holdings) Total Inventories : $0.00 Mil (As of Mar. 2024)

View and export this data going back to 2007. Start your Free Trial

What is Lixte Biotechnology Holdings Total Inventories?

Lixte Biotechnology Holdings's total inventories for the quarter that ended in Mar. 2024 was $0.00 Mil. Lixte Biotechnology Holdings's average total inventories from the quarter that ended in Dec. 2023 to the quarter that ended in Mar. 2024 was $0.00 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Lixte Biotechnology Holdings's Net-Net Working Capital per share for the quarter that ended in Mar. 2024 was $-0.24.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Inventory Turnover measures how fast the company turns over its inventory within a year.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Lixte Biotechnology Holdings Total Inventories Historical Data

The historical data trend for Lixte Biotechnology Holdings's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lixte Biotechnology Holdings Total Inventories Chart

Lixte Biotechnology Holdings Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Inventories

Get a 7-Day Free Trial

Lixte Biotechnology Holdings Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Inventories	Get a 7-Day Free Trial															-	-	-	-	-

Lixte Biotechnology Holdings Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.

Lixte Biotechnology Holdings (NAS:LIXT) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

Lixte Biotechnology Holdings's Net-Net Working Capital Per Share for the quarter that ended in Mar. 2024 is

	Net-Net Working Capital Per Share (Q: Mar. 2024 )
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(3.414	+	0.75 * 0	+	0.5 * 0	-	0.463
-	3.5	-	0)	/	2.24929
=	-0.24

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Lixte Biotechnology Holdings's Days Inventory for the three months ended in Mar. 2024 is calculated as:

Days Inventory	=	Average Total Inventories (Q: Mar. 2024 )	/	Cost of Goods Sold (Q: Mar. 2024 )	*	Days in Period
	=	0	/	0	*	365 / 4
	=

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

Lixte Biotechnology Holdings's Inventory Turnover for the quarter that ended in Mar. 2024 is calculated as

Inventory Turnover	=	Cost of Goods Sold (Q: Mar. 2024 )	/	Average Total Inventories (Q: Mar. 2024 )
	=	0	/	0
	=	N/A

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Lixte Biotechnology Holdings's Inventory to Revenue for the quarter that ended in Mar. 2024 is calculated as

Inventory-to-Revenue	=	Average Total Inventories (Q: Mar. 2024 )	/	Revenue (Q: Mar. 2024 )
	=	0	/	0
	=

Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.

Lixte Biotechnology Holdings Total Inventories Related Terms

Thank you for viewing the detailed overview of Lixte Biotechnology Holdings's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.

Lixte Biotechnology Holdings (Lixte Biotechnology Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lixte Biotechnology Holdings Inc (NAS:LIXT) » Definitions » Total Inventories

Comparable Companies

Traded in Other Exchanges

N/A

Address

680 East Colorado Boulevard, Suite 180, Pasadena, CA, USA, 91101

Website

https://www.lixte.com

Lixte Biotechnology Holdings Inc is a drug discovery company that has a developed unique, proprietary, first-in-class protein phosphatase inhibitor, LB-100, as its lead clinical compound. LB-100 has potential widespread use as an anti-cancer agent when used alone and in combination with standard anti-cancer therapies, including cytotoxic drugs, radiation, and immune checkpoint blockers. The Company's product pipeline is primarily focused on inhibitors of protein phosphatases, used alone and in combination with cytotoxic agents and x-ray and immune checkpoint blockers.

Executives

Rene Bernards	director	KONINGSVAREN 37, ABCOUDE P7 1391AD
Van Der Baan Bastiaan Jeroen	director	HOGEWEG 4-H, AMSTERDAM P7 1098CB
Eric Forman	10 percent owner	117 E. 29TH ST., APT. 5A, NEW YORK NY 10016
Regina Brown	director	248 ROUTE 25A, NO. 2, EAST SETAUKET NY 11733
Glenn Krinsky	10 percent owner	C/O SRKP 1, INC., 1900 AVENUE OF THE STARS, SUITE 310, LOS ANGELES CA 90067
Yun Yen	director	1301 OAKLAWN ROAD, ARCADIA CA 91006
Robert Greenberg	10 percent owner	SKECHERS USA INC, 228 MANHATTAN BEACH BLVD, MANHATTAN BEACH CA 90266
Gil Schwartzberg	10 percent owner	269 S. BEVERLY DR., #1315, BEVERLY HILLS CA 90212
Philip F Palmedo	director	1801 CENTURY PARK EAST #1600, LOS ANGELES CA 90067
John S Kovach	director, 10 percent owner, officer: Pres., CFO & Secty	1801 CENTURY PARK EAST #1600, LOS ANGELES CA 90067
Stephen J. Forman	director	248 ROUTE 25A, NO. 2, EAST SETAUKET NY 11733
Hung Tak Ho	10 percent owner	MAYFAIR BY THE SEA II, TOWER T8, 1/F, UNIT A, 21 FO CHUN ROAD, PAK SHEK KOK, TAIPO K3 00000
Robert N Weingarten	officer: Vice President and CFO	5439 LOCKHURST DRIVE, WOODLAND HILLS CA 91367
James Miser	officer: Chief Medical Officer	680 E COLORADO BLVD., SUITE 180, PASADENA CA 91101
Jane Merrill Riggs	10 percent owner	4852 SAINT ANDRES AVENUE, LA VERNE CA 91750